Skip to main content
close menu
close menu

Search UK HealthCare

Aman Chauhan, MD

Why are there no ratings?
  • About

    Aman Chauhan, MBBS, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India. He completed a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed a fellowship in hematology and oncology at UK with neuroendocrine tumor (NETs) training led by Lowell Anthony, MD. Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects.

    His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and non-small cell lung cancer. As Markey’s director of NET Theranostics, Dr. Chauhan will identify NET patients who qualify for Lutathera® (Lutetium 177 DOTATATE) treatments for gastroenteropancreatic neuroendocrine tumors (GEPNETs).

    Dr. Chauhan is board certified in internal medicine and specializes in the treatment of neuroendocrine tumors. He is a member of the medical oncology team at the UK Markey Cancer Center dedicated to multidisciplinary evaluation and treatment.

    He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society.

    Faculty Rank

    Assistant Professor of Medicine

    Degree

    Kasturba Medical College, Karnataka, India

    Residency

    Internal Medicine and Pediatrics, Louisiana State University, Health Sciences Center, New Orleans

    Fellowship

    Hematology and Oncology, University of Kentucky

    Certifications and Special Training

    American Board of Internal Medicine

    American Board of Medical Oncology

  • Publications

    Publications

    1. Can a High-grade Neuroendocrine Carcinoma be Functional? Graham C, Chauhan A, Anthony L. The American Journal of the Medical Sciences. 2019; 357(3):258-262.
    2. Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary Chauhan A, Farooqui Z, Silva SR, Murray A, Hodges KB, Yu Q, Myint ZW, Raajesekar AK, Weiss H, Arnold S, Evers BM, Anthony L. Asian Pacific Journal of Cancer Prevention : APJCP. 2019; 20(1):113-116.
    3. Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience. Myint ZW, McCormick J, Chauhan A, Behrens E, Anthony LB. Lung. 2018; 196(5):577-581.
    4. Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. Chauhan A, Farooqui Z, Murray LA, Weiss HL, War Myint Z, Raajasekar AKA, Evers BM, Arnold S, Anthony L. Journal of Oncology. 2018; 2018:3519247.
    5. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Oncotarget. 2018; 9(27):19245-19254.
    View all publications